Digital Library

Access our comprehensive collection of research resources, application notes, and product documentation.

Filter by type

  • Application Notes

Physiologically relevant iPSC-derived retinal models for ophthalmology research & drug discovery

Our new whitepaper describes how human iPSC‑derived retinal models enable mechanistic studies, toxicity assessment, and improved translational relevance in ophthalmology...

  • Application Notes

Modeling the genomic instability of Huntington’s Disease with iPSC technology

Axol Bioscience’s iPSC-derived striatal neurons model Huntington’s disease with CAG repeat instability and early-onset phenotypes. This study, we outline the...

  • Application Notes

Sartorius – iPSC-Derived Motor Neurons and Microglia From ALS Background Display Disease Phenotype

Explore Axol Bioscience’s iPSC-derived motor neurons and microglia from ALS patients for disease modeling and drug discovery. This whitepaper highlights...

  • Application Notes

Analysis of axoCells atrial and ventricular cardiomyocytes electrophysiology using CorePlate enabled HD-MEA System

Explore Axol Bioscience’s atrial and ventricular iPSC-derived cardiomyocytes analyzed using 3Brain’s HD-MEA CorePlate system. This application note highlights spontaneous beating,...

  • Application Notes

Multielectrode array characterization of human iPSC-derived motor neuron disease model for ALS drug discovery

Explore Axol Bioscience’s iPSC-derived motor neuron model for ALS drug discovery. This application note highlights hyperexcitability, mutation-specific phenotypes, and reproducible...

  • Application Notes

Functional and Pharmacological Differences Between the Contractility of axoCells™ iPSC-Derived Atrial and Ventricular Cardiomyocytes Assessed on the FLEXcyte 96

Axol Bioscience’s axoCells™ atrial and ventricular iPSC-derived cardiomyocytes reveal distinct contractility and drug responses on the FLEXcyte 96 platform. This...

  • Application Notes

axoCells™ ventricular cardiomyocytes as functionally-relevant cardiotoxicity models – external validation against CiPA compound panel

Axol Bioscience’s axoCells™ ventricular iPSC-derived cardiomyocytes were externally validated against the CiPA compound panel for cardiotoxicity screening. This study highlights...

Why digital?

Less printing. Lower CO₂. Faster access to the latest science.

● Instant updates, zero waste
● ~95% less paper per brochure